Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial.

Journal Article (Clinical Trial;Journal Article)

Objective: Lunasin, a soy peptide that reportedly alters histone acetylation in vitro, was associated with a single ALS reversal in the media. Following an ALSUntangled report, we sought to determine whether Lunasin altered histone acetylation and improved progression in people with ALS, and whether patient-centric trial design features might improve enrollment and retention. Methods: This single-center, year-long trial (NCT02709330) featured broad inclusion criteria, historical controls, primarily virtual data collection, and real-time results. Participants measured their own ALSFRS-R score, weight and perceived efficacy, and recorded these monthly on PatientsLikeMe. Blood tests at screening and month 1 assessed alterations in histone H3 and H4 acetylation. The protocol was published online, empowering patients outside the study to self-experiment. Results: Fifty participants enrolled in 5.5 months. Although this population had more advanced disease compared to other trials, retention and adherence were very high. There was no significant effect of Lunasin treatment on histone acetylation or disease progression. A cohort following our protocol outside the trial reported similar side effects and perceived effectiveness; however, their compliance with data entry was markedly lower. Conclusions: While Lunasin's lack of efficacy is disappointing, our novel trial design had the highest ALS trial enrollment rate ever recorded, with excellent retention and adherence. Low data density from patients who are self-experimenting outside a formal protocol casts doubt on the possibility of gathering useful information from unsupervised expanded access programs or "right to try" initiatives.

Full Text

Duke Authors

Cited Authors

  • Bedlack, RS; Wicks, P; Vaughan, T; Opie, A; Blum, R; Dios, A; Sadri-Vakili, G

Published Date

  • May 2019

Published In

Volume / Issue

  • 20 / 3-4

Start / End Page

  • 285 - 293

PubMed ID

  • 30663902

Electronic International Standard Serial Number (EISSN)

  • 2167-9223

Digital Object Identifier (DOI)

  • 10.1080/21678421.2018.1556698


  • eng

Conference Location

  • England